Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin for arterial vasoreactivity in obesity
NCT02576288Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis comparing Sitagliptin with Placebo (2 arms). Primary endpoints: Brachial artery flow mediated dilation at 28 days and Carotid stiffness (elasticity and distensibility) at 28 days. Started Jan 2016; status: completed.
02
Drugs
sitagliptin
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02576288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576288.